MX2024005076A - Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal. - Google Patents

Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal.

Info

Publication number
MX2024005076A
MX2024005076A MX2024005076A MX2024005076A MX2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A
Authority
MX
Mexico
Prior art keywords
coated
oral formulation
prophylaxis
treatment
intestinal fibrosis
Prior art date
Application number
MX2024005076A
Other languages
English (en)
Spanish (es)
Inventor
Roland Greinwald
Bernhard Tewes
Rudolf Wilhelm
Original Assignee
Dr Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh filed Critical Dr Falk Pharma Gmbh
Publication of MX2024005076A publication Critical patent/MX2024005076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024005076A 2021-10-25 2022-10-24 Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal. MX2024005076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2021/079584 WO2023072368A1 (en) 2021-10-25 2021-10-25 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
PCT/EP2022/079666 WO2023072878A1 (en) 2021-10-25 2022-10-24 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Publications (1)

Publication Number Publication Date
MX2024005076A true MX2024005076A (es) 2024-05-13

Family

ID=78536154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005076A MX2024005076A (es) 2021-10-25 2022-10-24 Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal.

Country Status (11)

Country Link
US (1) US20250041228A1 (cg-RX-API-DMAC7.html)
EP (1) EP4312994A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536609A (cg-RX-API-DMAC7.html)
KR (1) KR20240093898A (cg-RX-API-DMAC7.html)
CN (1) CN118234489A (cg-RX-API-DMAC7.html)
AU (1) AU2022374695A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230682A1 (cg-RX-API-DMAC7.html)
IL (1) IL312176A (cg-RX-API-DMAC7.html)
MX (1) MX2024005076A (cg-RX-API-DMAC7.html)
WO (2) WO2023072368A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402786B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297020A (en) 2020-04-24 2022-12-01 Dr Falk Pharma Gmbh A systemic preparation of a pyridonone derivative related to tg2
HRP20231072T1 (hr) 2020-04-24 2023-12-22 Dr. Falk Pharma Gmbh Sustavna formulacija derivata piridinona za celijakiju
WO2025153465A1 (en) * 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren

Also Published As

Publication number Publication date
IL312176A (en) 2024-06-01
JP2024536609A (ja) 2024-10-04
KR20240093898A (ko) 2024-06-24
US20250041228A1 (en) 2025-02-06
WO2023072368A1 (en) 2023-05-04
WO2023072878A1 (en) 2023-05-04
CN118234489A (zh) 2024-06-21
EP4312994A1 (en) 2024-02-07
AU2022374695A1 (en) 2024-03-21
CA3230682A1 (en) 2023-05-04
ZA202402786B (en) 2025-07-30

Similar Documents

Publication Publication Date Title
ES2593582T3 (es) Formulación de comprimido recubierto y método
CN1404389B (zh) 时控脉冲给药系统
CN101711752B (zh) 一种苯并异噁唑类衍生物的控释制剂及其制备方法
ZA202402786B (en) Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
KR20170033358A (ko) 브루톤 티로신 키나아제 저해제의 신규한 제제
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2017128614A5 (cg-RX-API-DMAC7.html)
CN104288774B (zh) 一种肠溶包衣、富马酸二甲酯肠溶制剂及其制备方法
RS56019B1 (sr) Premazana farmaceutska kompozicija koja sadrži regorafenib
KR102024699B1 (ko) 클로피도그렐 및 아스피린을 포함하는 복합제제
JP2019509345A5 (cg-RX-API-DMAC7.html)
CN101428005A (zh) 泮托拉唑及其钠盐肠溶缓释微丸制剂
CN101496789A (zh) 西他沙星缓释微丸及其制备方法
EP2533766B1 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
CN105025883A (zh) 右哌甲酯或其盐的调节释放的药物组合物
CN105640909B (zh) 一种含有达比加群酯的药用组合物
WO2015085739A1 (zh) 一种多层固体药物剂型
RS66154B1 (sr) Formulacije stimulansa sa tropulsnim oslobađanjem
ES2900975T3 (es) Preparación farmacéutica oral con revestimiento entérico que comprende fumarato de dimetilo
CN104856971B (zh) 一种脉冲双释放制剂及其制备方法与应用
WO2012150246A1 (de) Arzneiform zur gezielten freigabe von wirkstoffen
CN1311824C (zh) 奥美拉唑肠溶微粒制剂及制备方法
Sonawane et al. Formulation aspects and effect of critical factors for designing extended release pellets: an updated review
CN103127004B (zh) 一种藻酸双酯钠缓释颗粒及其制备方法
CA3007483C (en) Process for preparation of an enteric coated granulate comprising dimethyl fumarate